InterCure Ltd. (INCR)
| Market Cap | 95.70M |
| Revenue (ttm) | 101.90M |
| Net Income (ttm) | 9.33M |
| Shares Out | 45.57M |
| EPS (ttm) | 0.23 |
| PE Ratio | 9.23 |
| Forward PE | 6.94 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 45,560 |
| Open | 2.19 |
| Previous Close | 2.16 |
| Day's Range | 2.05 - 2.21 |
| 52-Week Range | 1.73 - 7.59 |
| Beta | -0.09 |
| Analysts | Buy |
| Price Target | 0.03 (-98.57%) |
| Earnings Date | Apr 5, 2023 |
About INCR
InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Israel and internationally. It offers dried cannabis inflorescences and cannabis extract mixed with oil. The company also invests in biomed sector. InterCure Ltd. was incorporated in 1994 and is headquartered in Herzliya, Israel. [Read more]
Full Company ProfileAnalyst Forecast
According to 8 analysts, the average rating for INCR stock is "Buy." The 12-month stock price forecast is $0.03, which is a decrease of -98.57% from the latest price.
News
InterCure Files Lawsuit Against Cann Pharmaceuticals to Recover Funds Following Failed Merger
NEW YORK, TORONTO, and HERZLIYA, Israel, Feb. 14, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc)(“InterCure” or the “Company”) the biggest and most pro...
InterCure Announces the Termination of its Acquisition Agreement with Cann Pharmaceutical (dba Better)
NEW YORK and TORONTO and HERZLIYA, Israel, Feb. 01, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company") announces that, furth...
InterCure Announces Exclusive International Partnership Agreement with Award Winning Cannabis Brand "Binske"
Leading Global Pharmaceutical Cannabis Company, InterCure, entered into an agreement with Praetorian Global, Inc. to license, manufacture and distribute the Florida-based cannabis brand ”Binske” Leadi...
InterCure to Participate in Cowen 5th Annual Cannabis Conference
Mr. Rabinovitch is one of the global cannabis senior executives to participate Mr. Rabinovitch is one of the global cannabis senior executives to participate
InterCure Announces the Withdrawal of a Class Action Lawsuit against it
NEW YORK and TORONTO and HERZLIYA, Israel, Dec. 05, 2022 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company") is pleased to announc...
Update regarding Better Transaction
NEW YORK and TORONTO and HERZLIYA, Israel, Nov. 23, 2022 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc)("InterCure" or the "Company") is hereby providing an...
Organigram and Intercure (dba : Canndoc) Sign New International Strategic Agreement Representing Largest Such Deal to Date for Both Companies
Organigram to supply Israeli pharmaceutical grade cannabis leader InterCure with up to 20,000 kg of dried flower over multiple years Organigram to supply Israeli pharmaceutical grade cannabis leader I...
Organigram and InterCure (dba : Canndoc) Sign New International Strategic Agreement Representing Largest Such Deal to Date for Both Companies
TORONTO & HERZILA, Israel--(BUSINESS WIRE)--Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), ( “Organigram”) a leading Canadian licensed producer of cannabis and Canndoc Ltd. (“Canndoc”), a subsid...
CORRECTION and MULTIMEDIA UPDATE -- InterCure Announces Record Breaking Third Quarter Financial Results with 63% growth YOY and 6% QoQ growth
NEW YORK and TORONTO and HERZLIYA, Israel, Nov. 15, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today, by InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR), ple...
InterCure Announces Record Breaking Third Quarter Financial Results with 63% growth YOY and 6% QoQ growth
Eleventh consecutive quarter of sequential profitable revenue growth
InterCure Announces Record Preliminary Third Quarter Revenue of Over CAD$39 million – 63% Growth YoY
Estimated revenue reaches CAD$39 million 1 (a record of over NIS 100 million) :
Intercure Ltd. Announces Voting Results from its Annual and Special Meeting of Shareholders
HERZLIYA, Israel, Sept. 16, 2022 (GLOBE NEWSWIRE) -- Intercure Ltd. (the “Company”) announces today the results of the Annual and Special General Meeting of shareholders of the Company, held on Thursd...
InterCure Reports Record Breaking Second Quarter Financial Results
Record revenue of over $3 7 million i in the second quarter of 2022
InterCure to Release its Q2 2022 Results and Hold a Conference Call
Conference call scheduled for Tuesday, August 16, 2022, at 8:30am ET Conference call scheduled for Tuesday, August 16, 2022, at 8:30am ET
InterCure Reports Record Preliminary 2022 Second Quarter Revenue – More Than Double YoY and 9% QoQ Growth
Estimated r evenue reach es CAD$3 6 million 1 ( a record NIS 95 million)
InterCure and Cookies Launch Flagship Retail Location in Vienna, Austria
NEW YORK and TORONTO and HERZLIYA, Israel, June 21, 2022 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) ("InterCure" or the “Company”) announced today the successful open...
InterCure and Cookies Successfully Launch Flagship Pharmacy in Be'er Sheva, Israel
Cookies Be'er Sheva is the largest medical cannabis dedicated pharmacy in Israel Cookies Be'er Sheva is the largest medical cannabis dedicated pharmacy in Israel
InterCure Begins 2022 with Record Breaking First Quarter Financial Results
Record revenue of $3 4 1 million in the first quarter of 2022
InterCure to Release its Q1 2022 Results and Hold a Conference Call
Conference call scheduled for Tuesday, May 17, 2022, at 8:00am ET Conference call scheduled for Tuesday, May 17, 2022, at 8:00am ET
InterCure to Participate in Upcoming Investor Conferences in May 2022
NEW YORK, TORONTO, and HERZLIYA, Israel, May 09, 2022 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc)("InterCure" or the “Company”) today announced that that...
InterCure to Participate in A.G.P.'s Spring Consumer Cannabis Conference
NEW YORK and TORONTO and HERZLIYA, Israel, May 03, 2022 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc) ("InterCure" or the “Company”) today announced that A...
InterCure Reports Record Breaking Q4 and 2021 Results – Exceeded Preliminary Results
Another record year with continued industry leading growth and profitability supported by focused strategy and execution
InterCure Expects to Publish its full Audited Fourth Quarter and Full Year 2021 Results Prior to the TSX Closing on April 5, 2022
Delay in publication of the Audited Results due to immaterial technical audit matters
CORRECTING and REPLACING -- InterCure Estimates Record Fourth Quarter and Fiscal Year End 2021 Results(1)
Fourth quarter 2021 Revenue and Adjusted EBITDA 2 of $33 million and $9 million, representing an increase of almost 200% and 140% YoY, respectively
InterCure Estimates Record Fourth Quarter and Fiscal Year End 2021 Results(1)
Fourth quarter 2021 Revenue and Adjusted EBITDA 2 of $33 million and $9 million, representing an increase of almost 200% and 140% YoY, respectively